Primary gastrointestinal non-Hodgkin lymphoma: a retrospective study in Vietnam

Ann Med Surg (Lond). 2023 May 17;85(6):2390-2394. doi: 10.1097/MS9.0000000000000858. eCollection 2023 Jun.

Abstract

Although primary gastrointestinal non-Hodgkin lymphoma (GI NHL) is a rare hematopoietic malignancy, it is the most common extranodal site involved by lymphoma. Treatment methods are chosen based on many factors, including site of lesion, histopathology, symptoms, and patients' choice.

Objectives: To evaluate the clinical characteristics, treatment results and prognosis for primary GI NHL in Vietnamese patients.

Patients and methods: This was a retrospective descriptive study on 126 patients with primary GI NHL treated at our hospital from 2010 to 2015. Data of all patients were collected and analyzed.

Results: B-cell non-Hodgkin's lymphoma was the major pathology with rate of 93.7%, in which Diffuse Large B-Cell Lymphoma type accounted for 58.7%, followed by Mucosa-associated lymphoid tissue lymphoma type 22.2%. Less common forms were cystic type, Burkitt's lymphoma, Mantle cell, T cell. The majority of patients receiving chemotherapy achieved a complete response, up to 70%. Overall survival and 5-year disease-free survival were 74.1% and 59.3%, respectively. Overall, stomach lymphoma had a longer survival rate than those in the small intestine. Factors including Eastern Cooperative Oncology Group score of 2-4, elevated Lactate Dehydrogenase levels at baseline, stage of widespread illness (III/IV), high malignancy histopathology, and lesion size of more than 10 cm were poor prognostic indicators.

Conclusions: Gastric lesion was the most frequent site and has better prognosis than other locations. Other prognostic factors for overall survival included Eastern Cooperative Oncology Group score, Lactate Dehydrogenase levels, stage, histopathology, and lesion size.

Keywords: Vietnam; gastrointestinal tract; hematopoietic malignancy; non-Hodgkin lymphoma; primary.